, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of KBR, Inc. (NYSE: KBR). Shareholders who purchased shares of KBR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose tha ...

Core Viewpoint - A class action lawsuit has been filed against Savara Inc. for alleged violations of securities laws, specifically related to misleading statements regarding its Biologics License Application (BLA) for MOLBREEVI [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from March 7, 2024, to May 23, 2025, with a deadline for lead plaintiff appointments set for November 10, 2025 [2]. - The complaint alleges that Savara made false and misleading statements to the market, particularly regarding the adequacy of information provided in its BLA submitted to the FDA [2]. - It is claimed that the FDA was unlikely to approve Savara's BLA due to deficiencies in the information provided, which rendered the company's public statements materially misleading throughout the class period [2]. Group 2: Shareholder Participation - Shareholders who purchased shares during the specified class period are encouraged to contact the law firm for potential lead plaintiff appointments, although this is not a requirement for recovery [2][3]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's status, with no cost or obligation to participate [3]. Group 3: Law Firm Background - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4]. - The firm represents some of the largest hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of PubMatic, Inc. regarding a class action lawsuit due to allegations of misleading statements and failure to disclose significant changes affecting the company's revenue and operations [1]. Group 1: Allegations and Impact - The complaint alleges that during the class period from February 27, 2025, to August 11, 2025, PubMatic's management made materially false and misleading statements [1]. - A top demand side platform buyer shifted a significant number of clients to a new platform, which evaluated inventory differently, leading to a reduction in ad spend and revenue for PubMatic [1]. - As a result of these changes, the positive statements made by the defendants regarding the company's business and prospects were deemed materially misleading and lacked a reasonable basis [1]. Group 2: Class Action Details - Shareholders who purchased shares of PUBM during the specified class period are encouraged to register for the class action, with a deadline set for October 20, 2025 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [2]. - There is no cost or obligation for shareholders to participate in this case [2]. Group 3: Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who incurred losses from misleading statements or omissions that led to artificial inflation of stock prices [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Nutex Health Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the Nutex securities is from August 8, 2024, to August 14, 2025, inclusive [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by October 21, 2025, to serve as lead plaintiff [2] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [3] Group 3: Case Allegations - The lawsuit alleges that Nutex made false and misleading statements regarding its financial practices and internal controls [4] - Specific claims include that Nutex engaged in fraudulent activities through a third-party vendor, HaloMD, which led to unsustainable revenue [4] - The allegations also state that Nutex overstated its ability to remediate internal control weaknesses and improperly classified stock-based compensation obligations [4]

Core Points - The Ademi Firm is investigating IAS for potential breaches of fiduciary duty and other legal violations related to its transaction with Novacap [1][2] - Shareholders of IAS are set to receive $10.30 per share in a deal valued at approximately $1.9 billion, with insiders benefiting significantly from change of control arrangements [2] - The transaction agreement restricts competing offers for IAS by imposing a substantial penalty if a competing bid is accepted, raising concerns about the board's fiduciary duties to shareholders [2]

Core Viewpoint - A class action lawsuit has been filed against Fly-E Group, Inc. for alleged securities fraud and unlawful business practices, following a significant decline in the company's net revenues attributed to recent lithium-battery accidents involving E-Bikes and E-Scooters [2]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Fly-E and certain officers or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until November 7, 2025, to request the Court to appoint them as Lead Plaintiff if they purchased Fly-E securities during the Class Period [2]. Group 2: Financial Performance - On August 14, 2025, Fly-E reported a 32% decrease in net revenues for the first quarter of fiscal year 2026, primarily due to a decrease in total units sold [2]. - Following the revenue announcement, Fly-E's stock price plummeted by $6.76 per share, or 87.11%, closing at $1.00 per share on August 15, 2025 [2].

Core Viewpoint - Fiserv, Inc. is under investigation for potential claims related to a federal securities class action, with a deadline for investors to seek lead plaintiff status set for September 22, 2025 [1] Group 1 - Faruqi & Faruqi, LLP, a prominent national securities law firm, is leading the investigation against Fiserv [1] - The investigation pertains to potential claims that may affect investors in Fiserv, Inc. [1] - The firm has multiple offices across New York, Pennsylvania, California, and Georgia [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of RxSight, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2] Group 1: Class Action Details - The class action lawsuit has been filed against RxSight, Inc. for allegedly misleading statements regarding the company's growth and performance during the Class Period [4] - Investors who purchased RxSight securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - The lead plaintiff must file a motion with the Court by September 22, 2025, to represent other class members in the litigation [2] Group 2: Allegations Against RxSight - The lawsuit claims that RxSight misrepresented the effectiveness of its field organization and the adoption rates of newer customer cohorts, which were actually underperforming [4] - It is alleged that the utilization across the installed base was declining, contradicting the company's claims of rising utilization [4] - As a result of these misleading statements, investors purchased shares at artificially inflated prices, leading to financial damages when the truth was revealed [4] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [3] - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [3] - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, further establishing the firm's credibility [3]

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of Rocket Pharmaceuticals, Inc. [1] Company Summary - Rocket Pharmaceuticals, Inc. is currently under scrutiny for possible misconduct by its leadership, which may affect shareholder interests [1]

Core Insights - Berger Montague (Canada) PC has expanded its investigation into Hut 8 Corp. following allegations of improprieties related to its management and operations [1][2]. Group 1: Allegations and Market Reaction - A report by J Capital Research on January 18, 2024, accused Hut 8 and U.S. Bitcoin Corp. of various improprieties, leading to a significant drop in Hut 8's share price from $12.56 to $9.24, a decline of over 26% within two trading sessions [2]. - On September 12, 2025, a U.S. federal court found certain allegations regarding King Mountain JV operations plausible, indicating that the Consolidated Amended Complaint adequately pleaded a material omission under Section 11 of the Securities Act [3]. Group 2: Legal Representation and Investor Rights - Investors who purchased shares of Hut 8 Corp. prior to January 18, 2024, are encouraged to contact Berger Montague to understand their rights regarding potential class action claims [4]. - Berger Montague is recognized for representing investors in shareholder class actions involving Canadian companies listed on various stock exchanges [4].